Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a light therapy clean cancer cells from blood? new trial aims to find out

NCT ID NCT05157581

Disease control Sponsor: Oleg E. Akilov, MD, PhD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether a procedure called extracorporeal photopheresis (ECP) can reduce tumor cells in people with Sezary syndrome, a rare blood cancer that affects the skin. Twenty participants will receive ECP weekly for a month, then every two weeks for five months. Researchers will analyze blood samples to see how the immune system responds and whether cancer cells decrease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Extracorporeal photopheresis (ECP) with methoxsalen
What this could lead to
If successful, this could show that ECP effectively reduces cancer cells in the blood and skin for people with Sezary syndrome, offering a treatment option.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. ECP is a complex procedure and may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with Sezary syndrome

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient with an established diagnosis of Sezary syndrome (stage IVA1) 2. Patients amenable for ECP 3. The patient must have a minimum wash-out period of 3 weeks between the last dose of prior systemic therapy 4. Patients should have recovered from all adverse events related to prior therapy to ≤ grade 1 5. Signed informed consent form prior to any protocol-specific procedures. Exclusion Criteria: 1. Visceral metastasis of lymphoma 2. Concomitant administration of radiotherapy or systemic anti-cancer therapy including but not restricted to: chemotherapy, biological agents, or immunotherapy 3. Patients with known NCI CTCAE grade 3 or higher active systemic or cutaneous viral, bacterial, or fungal infection. 4. Patients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment and/or comply with study protocol. 5. Patients with dementia or altered mental status that would preclude understanding and rendering of informed consent document. 6. Patients with known allergy to Methoxsalen or heparin (as part of SOC ECP procedure). 7. Patients who are pregnant. -

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sezary syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Sezary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sezary syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cutaneous Translational Research Program - Johns Hopkins Medicine

    RECRUITING

    Baltimore, Maryland, 21287, United States

  • Emory University School of Medicine

    NOT_YET_RECRUITING

    Atlanta, Georgia, 30322, United States

  • University of Pittsburgh Medical Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.